- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024$21.7 (-1.05%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024$19.03Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023$19.64 (-1.13%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023$27.16Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023$27.94Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023$25.25Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019Earnings
Q1 2023 BioArctic AB Earnings Call Transcript
Welcome to BioArctic Q1 report 2023. (Operator Instructions)
Now I will hand the conference over to CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead.
()-
Good morning, and welcome to BioArctic's presentation for the first quarter of 2023. I'm Gunilla Osswald, and I'm CEO of BioArctic, and I will share today's presentation with our CFO, Jan Mattsson; and our Chief Medical Officer, Tomas Odergren.
We will give an update on BioArctic and on lecanemab, and focus on the great start of this year with the approval in the U.S. by the accelerated pathway and the submission of applications for full market approval of lecanemab in 3 continents. These submissions are based on the groundbreaking results for lecanemab in the Clarity AD Phase III study in Early Alzheimer's disease. And I think it's really exciting that lecanemab, or Leqembi as it's named in the U.S., now it's available for patients in the U.S., and we'll talk more about that here today.
Next slide,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)